JournalArta
Friday, November 20, 2026 · JakartaS&P 7,175.83 ▼2.02%USD/IDR 18,272 ▲0.09%
JournalArta
Global Edition
beyond headlines
Advertisement

Colgate-Palmolive (CL) Stock Falls 1.99% (November 19, 2026): Down 1% in Five Sessions

Technical analysis of CL stock on November 19, 2026: price 96.88 USD, trend uptrend, RSI 53.0, support 91.69, resistance 100.99.

By matthew jonathan
WIB5 min read
Colgate-Palmolive (CL) Stock Falls 1.99% (November 19, 2026): Down 1% in Five Sessions
Logo Colgate-Palmolive — JournalArta illustration

Why CL is in focus today

    Selected automatically from 11 NYSE (US) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.

    Colgate-Palmolive shares fell 1.99% to $96.88 on the New York Stock Exchange in the Thursday, November 19, 2026 session, giving back part of the previous day's gains after a retreat in the prior session. The move came on volume of 6,383,700 shares, about 1.2 times the 20-day average of 5,462,670 — a heavier-than-usual session. The pullback leaves the consumer staples maker hovering almost exactly on its 20-day moving average of 96.72, a line that has been rising 1.21% over the past five days. That combination — a stock sliding into its short-term average while that average still points higher — is the central tension in the chart right now. The trend structure has not broken, but the momentum behind it has cooled.
    Advertisement

    Trend & Price Action

    The broader structure remains constructive. Colgate trades above both its 20-day average (96.72) and its 50-day average (91.83), and the 20-day sits above the 50-day, the classic arrangement of an uptrend. No new moving-average crossover has formed, so the trend signal is a continuation story rather than a fresh breakout. The stock also holds about 56% of its 20-day range between support at 91.69 and resistance at 100.99, and it sits in the upper half of its three-month band of 83.99 to 101.81. But the day's close is the tell: price is effectively touching, not bouncing decisively off, the 20-day line. The single bullish signal in the data set — a pullback to the 20-day average within an uptrend, with price above the 50-day — only completes if buyers step in here.
    Price action chart of CL
    3-month price action chart of CL: price, SMA20/50, Bollinger, support & resistance.
    Advertisement

    Oscillators & Momentum

    Momentum is where the picture darkens. The MACD reads 1.949 against a signal line of 2.133, and the histogram at −0.184 has just turned negative — an early warning that upward momentum is fading even as the trend holds. The data records this as one of two bearish signals, the other being the 14-day RSI rolling over from above 65. It now sits at 53.0, a neutral reading that leaves room in either direction. The stochastic tells a subtler story: %K has dropped to 24.8 while %D holds at 53.6. That gap is a sharp short-term deceleration, but because the longer oscillator has not followed it down, the reading is classified as neutral rather than oversold. In plain terms, the stock has cooled fast without yet signalling a rebound.
    Momentum chart of CL
    Momentum chart of CL: RSI(14), MACD, Stochastic.
    Advertisement

    Volatility & Volume

    Volatility is moderate. The 14-day ATR of 2.22 equals 2.3% of the share price, implying a normal daily range for a large-cap staple. Bollinger bands, at 101.96 above and 91.49 below, are neither squeezed nor stretched — the 10.8% width is normal — and the %B of 52% places price just above the middle of the envelope. There is room to move in either direction before conditions become stretched. The volume picture is more telling. The heavier session and the falling On-Balance Volume line suggest distribution — sellers using the slip to lighten positions — rather than accumulation on weakness. A pullback to support with rising OBV would read as healthy consolidation; the opposite is happening.
    Advertisement

    Fundamental Context

    The selling is not a reaction to weak earnings. Colgate-Palmolive reported quarterly revenue of $5.37 billion for the quarter ended September 30, 2026, up 4.6% from $5.13 billion a year earlier, and net income of $751.0 million versus $735.0 million, according to its SEC filing dated October 30. Diluted earnings per share were $0.94. Steady top- and bottom-line growth gives the technical consolidation a fundamentally stable backdrop.

    Key Levels & Scenarios

    Support sits at 91.69 for the 20-day window; a decisive break there would invalidate the bullish trend structure and open a retest toward the 50-day average at 91.83 — a cluster that makes the low-90s the line in the sand. Resistance is 100.99 on the 20-day measure, with the three-month high of 101.81 just above. A close above 100.99 would confirm the pullback has ended and set the stage for a retest of the high; a failure to hold the mid-90s keeps the stock pinned in its current drift.
    Advertisement

    Technical Verdict: HOLD (wait & see)

    The verdict is HOLD (wait & see), because trend and momentum are not yet aligned. Three reasons underpin the call: first, price remains above both the 20-day and 50-day averages and the 20-day average is still rising 1.21% over five days, so the uptrend is intact; second, the MACD histogram has just turned negative and the RSI has rolled over from above 65, meaning momentum has not yet caught up with the trend; third, the stochastic %K at 24.8 versus %D at 53.6 confirms short-term weakness rather than a reversal. The verdict is invalidated if price breaks decisively below the 20-day support at 91.69. - Entry range: a close above the 20-day resistance of 100.99 (upside scenario); alternatively, a confirmed hold of support near 93.54, the price minus 1.5×ATR level - Exit target: 100.22 (price plus 1.5×ATR) in the upside scenario, with the three-month high at 101.81 as the outer marker - Stop loss: a break below 91.69, which sits just under the 50-day average at 91.83 For a non-trader: the stock is in an uptrend but has lost its forward push, so the data favours watching for a confirmed move above resistance before treating the pullback as finished.
    IndicatorReadingSignal
    Last price96.88 USD−1.99% (1 day)
    20-day / 50-day SMA96.72 / 91.83Price above both; uptrend
    RSI(14)53.0Neutral; rolling over from above 65
    MACD histogram−0.184Just turned negative
    Stochastic %K / %D24.8 / 53.6Neutral; short-term deceleration
    Bollinger %B52%Just above middle band
    ATR(14)2.22 (2.3%)Moderate volatility
    Volume6,383,7001.2× 20-day average; OBV falling
    Support / Resistance — 20 days91.69 / 100.99Upper-half of range
    3-month high / low101.81 / 83.99—
    Advertisement
    Capping it off, the JournalArta research verdict scores Colgate-Palmolive +50 on a scale running from −100 to +100, below the +60 threshold required for a buy call.

    Summary Data CL

    Last price96.88 USD
    Change 1 day / 5 days / 1 month-1.99% / -1.04% / -0.52%
    Trend / MA-crossuptrend / none
    SMA20 / SMA5096.72 / 91.83
    RSI (14) / Stochastic %K53.0 / 24.8
    Bollinger %B / ATR52% / 2.22
    Support / Resistance 20 days91.69 / 100.99
    Data as of20 November 2026 04:00 WIB
    JournalArta research verdict (score)Hold (+50)

    Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.

    Advertisement
    What Kind of Holiday Spender Are You? Take the Black Friday QuizTake the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
    Advertisement
    Most Read
    1. 1Stock Market Today: Dow Slides 1.34% and VIX Jumps 15% at MiddayStock Market Today: Dow Slides 1.34% and VIX Jumps 15% at Midday
    2. 2Joachim Klement to Sell Stocks After S&P 500 SignalJoachim Klement to Sell Stocks After S&P 500 Signal
    3. 3Kenneth Walker’s Groin Injury Puts Cardinals Game in DoubtKenneth Walker’s Groin Injury Puts Cardinals Game in Doubt
    4. 4Pat Cummins Faces Captaincy Doubts From Mitchell JohnsonPat Cummins Faces Captaincy Doubts From Mitchell Johnson
    5. 5McDonald’s Workers’ Discrimination Claims Can Go AheadMcDonald’s Workers’ Discrimination Claims Can Go Ahead
    Advertisement
    Don't Miss

    Latest News

    All stories →
    1. UK-India Trade Deal Faces Test Over Bulk Scotch TariffsBusiness · Macro & PolicyUK-India Trade Deal Faces Test Over Bulk Scotch TariffsNov 20
    2. Liz Recalls Drinking at 15 as UK Consent Debate GrowsLifestyle · Food & HealthLiz Recalls Drinking at 15 as UK Consent Debate GrowsNov 20
    3. UK NCSC Passkeys and Cyber Essentials v3.3: Enterprise PlaybookTechnology · Apps & SoftwareUK NCSC Passkeys and Cyber Essentials v3.3: Enterprise PlaybookNov 20
    4. Daryl Maguire Jailed for Three Years Over Visa FraudWorld · AustraliaDaryl Maguire Jailed for Three Years Over Visa FraudNov 20
    5. Advertisement
    6. Finnish Study Backs Blood Test for Advanced Fatty Liver DiseaseLifestyle · Food & HealthFinnish Study Backs Blood Test for Advanced Fatty Liver DiseaseNov 20
    7. JPMorgan Chase (JPM) Stock Falls 1.20%: Near a 3-Month LowMarkets · StocksJPMorgan Chase (JPM) Stock Falls 1.20%: Near a 3-Month LowNov 20
    8. Anthropic Faces Protests After $2 Trillion Market DebutTechnologyAnthropic Faces Protests After $2 Trillion Market DebutNov 20
    9. UK CMA Cloud & Microsoft SMS Probe: Egress and Licensing ImpactTechnology · Apps & SoftwareUK CMA Cloud & Microsoft SMS Probe: Egress and Licensing ImpactNov 20